BioNTech is currently undervalued with a gap of 36.2% relative to the price target.
The current price is $89.96, which places BioNTech in the undervalued category. The stock is considered undervalued when the price is below $110.30, and overvalued when the price exceeds $134.81.
The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For BioNTech, the fair value range lies between $110.30 and $134.81.
21 analysts cover BioNTech. The majority is positive, with 76.2% recommending Buy, while 23.8% recommend Hold. The average price target is $122.55, which gives an upside of 36.2% from the current price.
BioNTech is classified as a speculative stock.
The P/S ratio is 8.2 (high — the market pays a premium for the revenue). The P/B ratio is 1.1. The PEG ratio is 0.05 — below 1.0 suggests the stock is cheap relative to its growth rate.
The latest quarterly earnings grew -43.2% year over year — falling earnings.
The Piotroski score is 1 out of 9 — weak financial health, be careful. Altman Z2 is 14.87 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 16.1% — low debt, a solid balance sheet.
Short interest is 3.32%.
BioNTech pays dividends to its shareholders. The most recently paid dividend was 2.11 USD per share.
We have registered dividend payments for BioNTech since 2022-06-02. In that period the stock has paid a dividend 1 times, most recently on 2022-06-02. However, the stock does not qualify as a stable or sporadic dividend stock, because the dividend payments have been inconsistent in recent years.
| Ex-date | Payment date | Amount | Currency | Period |
|---|---|---|---|---|
| 2022-06-02 | 2022-06-17 | 2.11 | USD | Unknown period |
In 2026, insiders at BioNTech have made 2 transactions, all of which were sales. On a net basis, insiders took 11,056,000 $ out of the stock. Active insiders include Sierk Poetting, Poetting Sierk.
There has been no insider trading in the last 3 months.
Insiders have exclusively sold shares in the recent period. This can suggest management sees limited opportunity.
Across the last 2 transactions: 0 purchases and 2 sales. A net 11,056,000 $ out of the stock.
Latest sale: Sierk Poetting sold 50,000 shares at 111 $ each on 2026-04-22.
Who is selling: Sierk Poetting, Poetting Sierk.
The table shows the last 2 reported insider transactions in BioNTech. Green rows are purchases, red rows are sales. The data is based on official filings.
| Transaction date | Name | Type | Number of shares | Price per share ($) | Total amount ($) |
|---|---|---|---|---|---|
| 2026-04-22 | Sierk Poetting | Sell | 50,000 | 111 | 5,528,000 |
| 2026-04-22 | Poetting Sierk | Sell | 50,000 | 111 | 5,528,000 |
The following insiders have sold shares: Sierk Poetting, Poetting Sierk. In total, 11,056,000 $ was sold across 2 transactions. Insider trades are legal transactions in which executives and board members buy or sell shares of their own company. These transactions are reported to the SEC and are publicly available.
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.
BioNTech SE is in a short-term uptrend. The price of $92.18 is 0.6% above the 20-day average ($91.67). Medium term, the picture is positive: the price is 0.9% above the 50-day average ($91.39). Long term, the stock is 6.0% below the 200-day average ($98.04), which signals a long-term downtrend.
Death Cross: The 50-day average (91.39) is below the 200-day average (98.04), which is a classic bearish signal for BioNTech SE.
BioNTech SE has an RSI of 51.1, right in the middle of the neutral zone. There is no clear buying or selling pressure.
Daily MACD: MACD is negative (-0.016), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is above the signal line (-0.026) by 0.010, which suggests the negative momentum is fading – a potential trend reversal could be ahead.
Weekly MACD: MACD5 is negative (-2.433), which indicates a broader bearish long-term trend. MACD5 is above the signal line (-2.642) by 0.209, which suggests the negative long-term momentum is fading – a bigger trend reversal could be ahead.
Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a daily basis – a potential trend reversal could be ahead, but it is not confirmed yet.
BioNTech SE has an annual standard deviation of 41.4%, which classifies the stock as medium risk. The price can swing noticeably when the market moves.
Trend: Negative. The price trades below SMA50 and SMA200.
MACD trend (zero line): Daily bearish (-0.016). Weekly bearish (-2.433).
MACD momentum (signal): Daily rising. Weekly rising.
RSI: 51.1 – neutral.
Technical signal: Strong Sell
The price is in a downtrend (below SMA50/SMA200) and MACD is negative on both a daily and weekly basis. Avoid buying and consider closing existing positions.